Ticker Details
Omeros Corporation Omeros Corp is a biopharmaceutical company. It focuses on research and development of small-molecule and protein therapeutics to treat inflammation, coagulopathies, and disorders of the central nervous system and sells Omidria for cataract surgeries.
IPO Date:	October 8, 2009
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$743.29M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.35 | 3.54%
Avg Daily Range (30 D):	$0.43 | 4.22%
Avg Daily Range (90 D):	$0.36 | 3.18%

Institutional Daily Volume
Avg Daily Volume:	.62M
Avg Daily Volume (30 D):	1.91M
Avg Daily Volume (90 D):	1.35M

Trade Size
Avg Trade Size (Sh.):	132
Avg Trade Size (Sh.) (30 D):	87
Avg Trade Size (Sh.) (90 D):	77

Institutional Trades
Total Institutional Trades:	1,435
Avg Institutional Trade:	$1.48M
Avg Institutional Trade (30 D):	$2.56M
Avg Institutional Trade (90 D):	$1.77M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.54M
Avg Closing Trade (30 D):	$2.36M
Avg Closing Trade (90 D):	$1.68M
Avg Closing Volume:	127.47K

News

Jul 8, 2026 @ 9:21 PM Heartflow vs. Omeros: Which Healthcare Innovator S... Source: Brendan Coffey

Jun 20, 2026 @ 3:02 PM Intellia Therapeutics vs. Omeros: Which Emerging B... Source: Brendan Coffey

Apr 20, 2026 @ 11:00 AM Sagimet Biosciences Announces Appointment of Andre... Source: Na

Dec 24, 2025 @ 10:22 PM Why Omeros Stock Skyrocketed Today Source: Eric Volkman

Nov 5, 2025 @ 6:30 AM Novo Nordisk's sales increased by 12% in Danish kr... Source: Novo Nordisk

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$1.3	$.78	$1.42
Diluted EPS	$1.14	$.62	$1.42
Revenue	$9.89M	$9.89M	$M
Gross Profit		$9.31M
Net Income / Loss	$86.17M	$56.06M	$86.45M
Operating Income / Loss	$-105.25M	$-17.42M	$-29.08M
Cost of Revenue		$.59M
Net Cash Flow	$-2.36M	$-7.75M	$7.27M
PE Ratio

Splits
Oct 02, 2009	25:49